Attovia Therapeutics, Inc. has set the terms for its initial public offering, pricing 17,000,000 shares of common stock at $17.00 per share, the company said in its statement. The placement was upsized, bringing expected gross proceeds to $289.0 million before underwriting discounts, commissions and other expenses.
All of the offered shares are being sold by Attovia. The underwriting group has been granted a 30-day option to acquire up to an additional 2,550,000 shares at the IPO price, less underwriting discounts and commissions.
Attovia’s shares are scheduled to begin trading on the Nasdaq Global Market on August 5, 2026 under the ticker symbol "ATTO." The offering is expected to close on August 6, 2026, subject to customary closing conditions.
The bank syndicate leading the deal lists Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets as joint book-running managers. LifeSci Capital is participating as a passive book-running manager.
On the clinical front, Attovia is focused on developing biotherapeutics for immune-mediated diseases. Its lead candidate, ATTO-1310, is an anti-IL-31 therapy moving through clinical development for chronic pruritic diseases. Two other programs, ATTO-2306 and ATTO-1091, are in IND-enabling studies targeting atopic dermatitis and inflammatory bowel disease, respectively.
The company’s registration statement with the Securities and Exchange Commission was declared effective on August 4, 2026.
Context and capitalization
The upsized offering and the inclusion of a standard 30-day overallotment option align with common IPO structures in the biopharmaceutical sector. The gross proceeds figure cited - $289.0 million before fees and expenses - reflects the amount before underwriting discounts, commissions and other offering costs are deducted. Attovia is selling all shares in the offering.
Pipeline snapshot
- ATTO-1310 - anti-IL-31 therapeutic in clinical development for chronic pruritic diseases.
- ATTO-2306 - in IND-enabling studies targeting atopic dermatitis.
- ATTO-1091 - in IND-enabling studies targeting inflammatory bowel disease.
Further procedural milestones include the expected public trading start date and the formal close of the offering, both subject to customary conditions.